Literature DB >> 28150849

From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.

Magdalena L Bochenek, Nico S Rosinus, Mareike Lankeit, Lukas Hobohm, Felix Bremmer, Eva Schütz, Frederikus A Klok, Sven Horke, Christoph B Wiedenroth, Thomas Münzel, Irene M Lang, Eckhard Mayer, Stavros Konstantinides, Katrin Schäfer1.   

Abstract

The pathomechanisms underlying the development of thrombofibrotic pulmonary artery occlusions in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) are largely unknown. The aim of this study was to allocate distinct cellular processes playing a role in thrombus resolution, such as inflammation, hypoxia, proliferation, apoptosis and angiogenesis, to different stages of thrombofibrotic remodelling. A total of 182 pulmonary endarterectomy (PEA) specimens were collected from 31 CTEPH patients. To facilitate co-localisation, Tissue MicroArrays were prepared and processed for (immuno)-histochemistry and confocal fluorescence microscopy. Murine venous thrombus formation and resolution was examined after inferior vena cava ligation. PEA tissues exhibited five morphologically distinct regions predominantly consisting of either fibrin-, erythrocyte- or extracellular matrix-rich thrombus, myofibroblasts, vessels or fibrotic tissue, and were found to resemble chronological stages of thrombus resolution in mice. Cellularity was highest in vessel-rich regions, and numerous cells were strongly positive for HIF1α or HIF2α as well as markers of activated VEGF signalling, including endothelial nitric oxide synthase. On the other hand, negative regulators of angiogenic growth factor signalling and reactive oxygen species were also highly expressed. Immune cells, primarily macrophages of the M2 subtype and CD117 haematopoietic progenitors were detected and highest in vascularised regions. Our findings demonstrate the simultaneous presence of different stages of thrombus organisation and suggest that hypoxia-induced endothelial, mesenchymal and immune cell activation may contribute to thrombofibrosis in CTEPH. This systematic histological characterisation of the material obstructing pulmonary vessels in CTEPH may provide a valuable basis for further studies aimed at determining causal factors underlying this disease.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; fibrosis; histological classification; venous thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28150849     DOI: 10.1160/TH16-10-0790

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Chronic Thromboembolic Pulmonary Hypertension: the Bench.

Authors:  George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal
Journal:  Curr Cardiol Rep       Date:  2021-08-19       Impact factor: 2.931

2.  Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Magdalena L Bochenek; Christiane Leidinger; Nico S Rosinus; Rajinikanth Gogiraju; Stefan Guth; Lukas Hobohm; Kerstin Jurk; Eckhard Mayer; Thomas Münzel; Mareike Lankeit; Markus Bosmann; Stavros Konstantinides; Katrin Schäfer
Journal:  Circ Res       Date:  2019-11-21       Impact factor: 17.367

Review 3.  Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis.

Authors:  Ayesha Zia; Joy Russell; Ravi Sarode; Surendranath R Veeram; Shellie Josephs; Kendra Malone; Song Zhang; Janna Journeycake
Journal:  Thromb Res       Date:  2017-10-07       Impact factor: 3.944

4.  NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation.

Authors:  George A Alba; Andriy O Samokhin; Rui-Sheng Wang; Ying-Yi Zhang; Bradley M Wertheim; Elena Arons; Edward A Greenfield; Martina H Lundberg Slingsby; Julia R Ceglowski; Kathleen J Haley; Frederick P Bowman; Yen-Rei Yu; John C Haney; George Eng; Richard N Mitchell; Anthony Sheets; Sara O Vargas; Sachiko Seo; Richard N Channick; Peter J Leary; Sudarshan Rajagopal; Joseph Loscalzo; Elisabeth M Battinelli; Bradley A Maron
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 21.405

Review 5.  Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence.

Authors:  Olga Porembskaya; Yana Toropova; Vladimir Tomson; Kirill Lobastov; Leonid Laberko; Viacheslav Kravchuk; Sergey Saiganov; Alexander Brill
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

6.  Quantitative and Qualitative Assessment of Adhesive Thrombo-Fibrotic Lead Encapsulations (TFLE) of Pacemaker and ICD Leads in Arrhythmia Patients-A Post Mortem Study.

Authors:  Jonas Keiler; Marko Schulze; Ronja Dreger; Armin Springer; Alper Öner; Andreas Wree
Journal:  Front Cardiovasc Med       Date:  2020-11-30

7.  Modulation of soluble guanylate cyclase ameliorates pulmonary hypertension in a rat model of chronic thromboembolic pulmonary hypertension by stimulating angiogenesis.

Authors:  John Zagorski; Evandro Neto-Neves; Nathan J Alves; Amanda J Fisher; Jeffrey A Kline
Journal:  Physiol Rep       Date:  2022-01

Review 8.  Dysregulation of the Nitric Oxide/Dimethylarginine Pathway in Hypoxic Pulmonary Vasoconstriction-Molecular Mechanisms and Clinical Significance.

Authors:  Juliane Hannemann; Rainer Böger
Journal:  Front Med (Lausanne)       Date:  2022-02-17

9.  Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow.

Authors:  Maximilian Ackermann; Steven J Mentzer; Martin Kolb; Danny Jonigk
Journal:  Eur Respir J       Date:  2020-11-12       Impact factor: 16.671

10.  Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Wenyi Pang; Zhu Zhang; Yunxia Zhang; Meng Zhang; Ran Miao; Yuanhua Yang; Wanmu Xie; Jun Wan; Zhenguo Zhai; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2020-11-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.